Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial

Table 5 Cumulative costs, QALYs and life-years 1–5

Time since randomization, years	Cumulative costs, $	Difference costs, $			Cumulative QALYs			Difference QALYs			Cumulative LYs			Difference LYs
Time since randomization, years	CABG PCI MT	CABG vs. MT	PCI vs. MT	PCI vs. CABG	CABG	PCI	MT	CABG vs. MT	PCI vs. MT	PCI vs. CABG	CABG	PCI	MT	CABG vs. MT	PCI vs. MT	PCI vs. CABG
1	2213 2208 645	1568	1563	− 5	0.77	0.78	0.77	0.00	0.01	0.01	0.97	0.96	0.99	− 0.02	− 0.03	− 0.01
2	2388 2428 958	1430	1470	40	1.54	1.54	1.51	0.03	0.03	0.00	1.90	1.88	1.94	− 0.04	− 0.06	− 0.02
3	2508 2585 1243	1265	1342	77	2.29	2.31	2.31	− 0.02	0.00	0.02	2.81	2.80	2.85	− 0.04	− 0.05	− 0.01
4	2609 2759 1443	1166	1317	150	3.04	3.07	2.88	0.16	0.19	0.03	3.70	3.72	3.71	− 0.01	0.01	0.02
5	2753 3002 1740	1013	1262	249	3.77	3.80	3.54	0.23	0.26	0.03	4.56	4.59	4.55	0.01	0.04	0.03

5000 replications
MT medical treatment, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, QALY quality-adjusted life-year, LYs life-years, $ American dollar

ISSN: 1478-7547